Artiva Biotherapeutics (ARTV) Competitors $1.78 +0.04 (+2.01%) As of 11:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ARTV vs. ACRS, BIOA, MOLN, ALEC, VTYX, LXEO, THTX, BDTX, ALTS, and LYELShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors Aclaris Therapeutics BioAge Labs Molecular Partners Alector Ventyx Biosciences Lexeo Therapeutics Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Aclaris Therapeutics (NASDAQ:ACRS) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Do insiders & institutionals have more ownership in ACRS or ARTV? 98.3% of Aclaris Therapeutics shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer ACRS or ARTV? Aclaris Therapeutics presently has a consensus target price of $8.71, indicating a potential upside of 446.35%. Artiva Biotherapeutics has a consensus target price of $17.80, indicating a potential upside of 902.82%. Given Artiva Biotherapeutics' higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Aclaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ACRS or ARTV? In the previous week, Aclaris Therapeutics had 4 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 0 mentions for Artiva Biotherapeutics. Aclaris Therapeutics' average media sentiment score of 0.77 beat Artiva Biotherapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aclaris Therapeutics Positive Artiva Biotherapeutics Neutral Is ACRS or ARTV more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -732.42%. Aclaris Therapeutics' return on equity of -30.73% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-732.42% -30.73% -22.74% Artiva Biotherapeutics N/A -75.95%-39.51% Which has stronger valuation & earnings, ACRS or ARTV? Artiva Biotherapeutics has lower revenue, but higher earnings than Aclaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$18.72M9.23-$132.07M-$1.39-1.15Artiva BiotherapeuticsN/AN/A-$65.37MN/AN/A SummaryAclaris Therapeutics beats Artiva Biotherapeutics on 9 of the 13 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.49M$2.97B$5.59B$9.00BDividend YieldN/A2.44%5.25%4.03%P/E RatioN/A21.5027.5420.18Price / SalesN/A255.29415.83171.78Price / CashN/A41.8337.0657.97Price / Book0.237.858.105.61Net Income-$65.37M-$55.05M$3.17B$248.59M7 Day Performance7.90%5.25%3.33%4.67%1 Month Performance-14.66%3.68%3.54%7.18%1 Year PerformanceN/A5.37%33.62%21.21% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics2.0561 of 5 stars$1.78+2.0%$17.80+902.8%N/A$43.49MN/A0.0081ACRSAclaris Therapeutics2.6353 of 5 stars$1.46+1.4%$9.71+565.4%+22.2%$155.93M$18.72M-1.05100Analyst ForecastGap UpBIOABioAge LabsN/A$4.18-2.3%N/AN/A$153.44MN/A0.00N/ANews CoverageMOLNMolecular Partners2.807 of 5 stars$3.61-4.0%$12.00+232.4%-44.3%$151.81M$2.23M-1.88180Gap DownALECAlector4.0616 of 5 stars$1.44-4.6%$4.00+177.8%-65.4%$150.99M$100.56M-1.14270News CoverageVTYXVentyx Biosciences2.4007 of 5 stars$2.04-1.9%$10.00+390.2%+2.6%$148.01MN/A-1.1730LXEOLexeo Therapeutics2.2775 of 5 stars$4.54+2.0%$16.60+265.6%-72.5%$147.73M$650K-1.3858High Trading VolumeTHTXTheratechnologiesN/A$3.17-0.9%N/A+105.2%$147.14M$85.87M-39.63140News CoverageEarnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.7253 of 5 stars$2.50-3.1%$12.80+412.0%-47.3%$146.71MN/A41.6790ALTSALT5 Sigma0.0651 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma2.5927 of 5 stars$9.15-5.6%$15.00+63.9%-68.1%$143.49M$60K-0.37270 Related Companies and Tools Related Companies ACRS Alternatives BIOA Alternatives MOLN Alternatives ALEC Alternatives VTYX Alternatives LXEO Alternatives THTX Alternatives BDTX Alternatives ALTS Alternatives LYEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTV Stock Alerts